B Cell Depletion Treatment in Resistant Systemic Sclerosis Interstitial Lung Disease.
| Autor: | Bounia CA; Division of Rheumatology, Patras University Hospital, Rion, Patras, Greece., Liossis SC; Division of Rheumatology, Patras University Hospital, Rion, Patras, Greece.; Departmnnent of Internal Medicine, University of Patras Medical School, Rion, Patras, Greece. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Mediterranean journal of rheumatology [Mediterr J Rheumatol] 2022 Mar 31; Vol. 33 (1), pp. 1-6. Date of Electronic Publication: 2022 Mar 31 (Print Publication: 2022). |
| DOI: | 10.31138/mjr.33.1.1 |
| Abstrakt: | Systemic sclerosis is a systemic, autoimmune disease that in many patients affects not only the skin, but also internal organs, mainly the lung. It is clear that internal organ (ie, lung) involvement determines the prognosis. Therefore, there is an unmet need to introduce novel and more effective treatments capable of halting disease progression and hence improve prognosis. Experimental data over the past decade has accumulated pointing to the B cell as a player in disease pathogenesis. Consequently, a number of controlled and uncontrolled studies have investigated the results of B cell depletion treatment in patients with SSc. The results are preliminary still encouraging for skin as well as for pulmonary involvement. In this review we will analyse and discuss such trials that have currently added B cell depletion as an alternative and promising treatment for resistant interstitial lung disease in scleroderma. (© 2022 The Mediterranean Journal of Rheumatology (MJR).) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|